Atossa Genetics Inc. (NASDAQ:ATOS) Receives Average Rating of “Hold” from Brokerages

Atossa Genetics Inc. (NASDAQ:ATOS) has earned a consensus rating of “Hold” from the five research firms that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $20.33.

ATOS has been the subject of a number of research analyst reports. Wall Street Zen upgraded Atossa Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Atossa Genetics in a research report on Tuesday, September 8th. Finally, Rodman & Renshaw began coverage on Atossa Genetics in a research note on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price for the company.

Atossa Genetics Price Performance

Shares of ATOS stock opened at $1.90 on Friday. The company has a fifty day moving average price of $2.42 and a two-hundred day moving average price of $3.64. Atossa Genetics has a one year low of $1.70 and a one year high of $19.35. The stock has a market cap of $18.96 million, a P/E ratio of -0.61 and a beta of 1.27.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.07. As a group, equities research analysts anticipate that Atossa Genetics will post -3.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

An institutional investor recently bought a new stake in Atossa Genetics stock. State Street Corp acquired a new stake in Atossa Genetics Inc. (NASDAQ:ATOS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned about 0.40% of Atossa Genetics at the end of the most recent reporting period. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc, now operating as Atossa Therapeutics, Inc (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer.